Enoxaparin Sodium
Rank #492 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$14.2M
Total Cost
93,202
Total Claims
$14.2M
Total Cost
3,767
Prescribers
$152
Cost per Claim
28,348
Beneficiaries
94,515
30-Day Fills
$3,773
Avg Cost/Provider
25
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$14.2M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $14.2M total
Top Prescribers of Enoxaparin Sodium
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Vincent Picozzi | Hematology-Oncology | Seattle, WA | 128 | $64K |
| 2 | Vivek Gupta | Internal Medicine | Chicago, IL | 516 | $58K |
| 3 | Anna Rita Marcelli | Internal Medicine | New York, NY | 112 | $44K |
| 4 | Marcello Gomes | Peripheral Vascular Disease | Cleveland, OH | 56 | $37K |
| 5 | Robert Danziger | Cardiology | Chicago, IL | 101 | $33K |
| 6 | Nauman Moazzam | Hematology-Oncology | Lakewood, CO | 72 | $32K |
| 7 | Melissa Breault | Nurse Practitioner | Troy, NY | 140 | $29K |
| 8 | Thomas Ortel | Hematology | Durham, NC | 45 | $29K |
| 9 | Balagopalan Nair | Hematology-Oncology | Little Rock, AR | 39 | $28K |
| 10 | Pablo Bedano | Hematology-Oncology | Indianapolis, IN | 43 | $28K |
| 11 | Suman Patel | Internal Medicine | Van Nuys, CA | 201 | $27K |
| 12 | Jack Janani | Internal Medicine | Brooklyn, NY | 162 | $26K |
| 13 | Bernard Agbemadzo | Internal Medicine | Albuquerque, NM | 49 | $26K |
| 14 | Cy Wilkins | Hematology | New York, NY | 71 | $26K |
| 15 | Steven Ritter | Sleep Medicine | Poughkeepsie, NY | 195 | $25K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 489 | Colesevelam Hcl (Colesevelam Hcl) | $14.3M | 50,268 |
| 490 | Bexarotene (Bexarotene) | $14.2M | 1,613 |
| 491 | Ozanimod Hydrochloride (Zeposia) | $14.2M | 1,535 |
| 492 | Enoxaparin Sodium (Enoxaparin Sodium) | $14.2M | 93,202 |
| 493 | Omadacycline Tosylate (Nuzyra) | $14.1M | 1,395 |
| 494 | Binimetinib (Mektovi) | $14.1M | 1,094 |
| 495 | Glecaprevir/Pibrentasvir (Mavyret) | $14.1M | 1,011 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology